SOLVSolventum
- Employees
- 10,000
- Headquarters
- Eagan, MN
- CEO
- Bryan C. Hanson
- Next results
- around Feb 25, 2027
What changed
10-K filed Feb 27, 2026 against Feb 28, 2025| Area | What changed | Source |
|---|---|---|
| Risk factors | 15 new paragraphs, nothing like them in the previous 10-K | 10-K Item 1A |
| Cash from operations lower than net income | Cash from operations $369.0M vs net income $1.6B (FY ending 2025-12-31) | 10-K · XBRL |
| Critical audit matters changed | New this year: Divestiture of Purification and Filtration Business - Gain on Sale (“As described in Notes 1, 3, and 8 to the consolidated financial statements, on February 25, 2025, the Company entered into a Transaction Agreement to sell its Purification and Filtration business to Thermo Fisher Scientific Inc. ("Buyer"). On June 25, 2025, the Company and Buyer entered into an Amen”); Acquisition of Acera Surgical - Valuation of Developed Technology (“As described in Note 3 to the consolidated financial statements, on December 23, 2025, the Company acquired Acera Surgical (“Acera”) for total purchase consideration of $776 million, which included cash consideration of $696 million, net of cash acquired, and a future milestone payment of an additio”); The principal considerations for our determination that performing procedures relating to the valuation (“of developed technology acquired in the acquisition of Acera is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the developed technology acquired; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedur”). No longer listed: Table of Contents. Same as last year: Revenue Recognition | 10-K · XBRL |
| Accounting checks | 9 other checks clear, 2 worth a look | 10-K · XBRL |
| Insiders | No open-market buys in the last 90 days | Form 4 |
| Filings | 2 in the last 30 days | EDGAR |
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
What's new, in their words
10-K filed Feb 27, 2026Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-28. Quoted as filed.
The deployment and use of artificial intelligence ("AI"), machine learning, or other emerging technologies in Solventum’s products and services, including as part of its research and development efforts, or its failure to adapt its products or services to industry trends and developments related to such technologies in a timely manner,…
10-K, Item 1A
Accounting checks
latest 10-K9 of 11 clear 2 worth a look. Checks, not verdicts.
- !Cash from operations lower than net incomeCash from operations $369.0M vs net income $1.6B (FY ending 2025-12-31)
- !Critical audit matters changedNew this year: Divestiture of Purification and Filtration Business - Gain on Sale (“As described in Notes 1, 3, and 8 to the consolidated financial statements, on February 25, 2025, the Company entered into a Transaction Agreement to sell its Purification and Filtration business to Thermo Fisher Scientific Inc. ("Buyer"). On June 25, 2025, the Company and Buyer entered into an Amen”); Acquisition of Acera Surgical - Valuation of Developed Technology (“As described in Note 3 to the consolidated financial statements, on December 23, 2025, the Company acquired Acera Surgical (“Acera”) for total purchase consideration of $776 million, which included cash consideration of $696 million, net of cash acquired, and a future milestone payment of an additio”); The principal considerations for our determination that performing procedures relating to the valuation (“of developed technology acquired in the acquisition of Acera is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the developed technology acquired; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedur”). No longer listed: Table of Contents. Same as last year: Revenue Recognition
- ✓Receivables -1.0% vs revenue +0.9% (-1.8 pts)
- ✓Inventory +10.5% vs revenue +0.9% (+9.6 pts)
- ✓Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
- ✓No statement of substantial doubt about going concern
- ✓No 8-K item 4.02 in the last 2 years
- ✓No NT 10-K or NT 10-Q in the last 2 years
- ✓No sentence in the 10-K concludes that controls were not effective because of a material weakness
- ✓No 8-K item 2.06 in the last 2 years
- ✓No 8-K item 1.03 in the last 2 years
In the last 30 days
All filings →- Nov 5, 20268-K Quarterly results 8-K item 2.02
- Nov 5, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q.
RSS feed
Work on SOLV in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/SOLV/export.csv") into a cell.